Nephrogenic systemic fibrosis: A fibrosing disorder induced by gadolinium exposure

International Journal of Advances in Rheumatology

Volumn 9, Issue 4, 2011, Pages 123-133

  Bernstein, Elana J ^a   Kay, Jonathan ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; RAPAMYCIN; SODIUM THIOSULFATE; THALIDOMIDE;

CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EXPOSURE; EPIDEMIOLOGICAL DATA; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; KIDNEY TRANSPLANTATION; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; PATHOPHYSIOLOGY; PHOTOTHERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; PUVA; REVIEW; SKIN BIOPSY; SKIN MANIFESTATION;

EID: 84863916692     PISSN: 1478856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Centers for Disease Control and Prevention (CDC). Fibrosing skin condition among patients with renal disease - United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 2002;51:25-6.
2. Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
3. Cowper SE, Su LD, Bhawan J et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-93. (Pubitemid 32938907)
4. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005;46:763-5. (Pubitemid 41383957)
5. Girardi M, Kay J, Elston DM et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095-106.e7.
6. Bangsgaard N, Marckmann P, Rossen K et al. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009;145:183-7.
7. Moschella SL, Kay J, Mackool BT et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004;351:2219-27.
8. Jimenez SA, Artlett CM, Sandorfi N et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660-6. (Pubitemid 39062729)
9. Kay J, Bazari H, Avery LL et al. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008;358:827-38.
10. Koreishi AF, Nazarian RM, Saenz AJ et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med 2009;133:1943-8.
11. Mendoza FA, Artlett CM, Sandorfi N et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238-49. (Pubitemid 43185214)
12. Sanyal S, Marckmann P, Scherer S et al. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis - an autopsy-based review. Nephrol Dial Transplant 2011;26:3616-26.
13. Marckmann P, Skov L, Rossen K et al. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008;69:161-8. (Pubitemid 351351062)
14. Barker-Griffith A, Goldberg J, Abraham JL. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol 2011;129:661-3.
15. Edsall LC, English JC 3rd, Teague MW et al. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004;31:247-53. (Pubitemid 38230567)
16. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569-77. (Pubitemid 39447280)
17. Ting WW, Stone MS, Madison KC et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-6. (Pubitemid 36898926)
18. Marckmann P, Skov L, Rossen K et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-8. (Pubitemid 350202540)
19. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130:209-12. (Pubitemid 43237993)
20. Saenz A, Mandal R, Kradin R et al. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006;449:389-91. (Pubitemid 44367984)
21. Lewis KG, Lester BW, Pan TD et al. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 2006;33:695-700. (Pubitemid 44536350)
22. Todd DJ, Kagan A, Chibnik LB et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56:3433-41. (Pubitemid 47585439)
23. Broome DR, Girguis MS, Baron PW et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-92. (Pubitemid 46167763)
24. Collidge TA, Thomson PC, Mark PB et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-75. (Pubitemid 47417800)
25. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-7.
26. Othersen JB, Maize JC, Woolson RF et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007;22:3179-85. (Pubitemid 350202590)
27. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
28. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62. (Pubitemid 44300951)
29. Khurana A, Runge VM, Narayanan M et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42:139-45. (Pubitemid 46104895)
30. Sadowski EA, Bennett LK, Chan MR et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-57. (Pubitemid 46579705)
31. Moreno-Romero JA, Segura S, Mascaro JM Jr et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007;157:783-7. (Pubitemid 47389867)
32. Abujudeh HH, Kaewlai R, Kagan A et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009;253:81-9.
33. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-4.
34. Bridges MD, St Amant BS, McNeil RB et al. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR Am J Roentgenol 2009;192:1538-43.
35. Prince MR, Zhang H, Morris M et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-16.
36. Anavekar NS, Chong AH, Norris R et al. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient. Australas J Dermatol 2008;49:44-7.
37. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425-32. (Pubitemid 47347864)
38. Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 2007;3:111-5. (Pubitemid 46161003)
39. Cassis TB, Jackson JM, Sonnier GB et al. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 2006;45:56-9.
40. Nazarian RM, Mandal RV, Kagan A et al. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol 2011;64:741-7.
41. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003;25:358. (Pubitemid 36897345)
42. High WA, Ayers RA, Chandler J et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-6. (Pubitemid 46017000)
43. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30. (Pubitemid 44969309)
44. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710-2. (Pubitemid 46400200)
45. Boyd AS, Sanyal S, Abraham JL. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. J Am Acad Dermatol 2008;59:356-8. (Pubitemid 351970110)
46. Sieber MA, Lengsfeld P, Frenzel T et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73.
47. Pietsch H, Lengsfeld P, Steger-Hartmann T et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009;44:226-33.
48. Weinmann HJ, Brasch RC, Press WR et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-24. (Pubitemid 14199123)
49. Issa N, Poggio ED, Fatica RA et al. Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI. Cleve Clin J Med 2008;75:95-7, 103-4, 106 passim.
50. US Food and Drug Administration. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. Silver Spring, MD 2010 (updated 12/23/10). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed August 1, 2011.
51. EMA. Assessment report for gadolinium-containing contrast agents (Procedure No: EMEA/H/A-31/1097). London: European Medicines Agency; July 1, 2010. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ Referrals-document/gadolinium-31/WC500099538.pdf. Accessed August 1, 2011.
52. Idée JM, Port M, Raynal I et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-76. (Pubitemid 44760175)
53. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007;18:2636-43. (Pubitemid 47531189)
54. Del Galdo F, Wermuth PJ, Addya S et al. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33.
55. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18.
56. Distler JH, Jungel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22. (Pubitemid 46106205)
57. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008;58:2543-8.
58. Piera-Velazquez S, Louneva N, Fertala J et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23.
59. Baron PW, Cantos K, Hillebrand DJ et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003;25:204-9. (Pubitemid 36706461)
60. Swartz RD, Crofford LJ, Phan SH et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114:563-72. (Pubitemid 36577259)
61. Berk DR, Miller A, Scarlett D et al. Osseous metaplasia late in the course of nephrogenic systemic fibrosis. Dermatol Online J 2010;16:3.
62. Gulati A, Harwood CA, Raftery M et al. Magnetic resonance imaging with gadolinium enhancement in renal failure: a need for caution. Int J Dermatol 2008;47:947-9.
63. Aires NB, Sotto MN, Nico MM. Nephrogenic fibrosing dermopathy: report of two cases. Acta Derm Venereol 2007;87:521-4. (Pubitemid 351373397)
64. Tsagalis G, Psimenou E, Laggouranis A. Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis. Int J Artif Organs 2008;31:913-4.
65. Läuchli S, Zortea-Caflisch C, Nestle FO et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004;208:278-80. (Pubitemid 38594553)
66. Wahba IM, White K, Meyer M et al. The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy - report of two cases and review of the literature. Nephrol Dial Transplant 2007;22:631-6. (Pubitemid 46189914)
67. Gilliet M, Cozzio A, Burg G et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005;152:531-6. (Pubitemid 40547128)
68. Mathur K, Morris S, Deighan C et al. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008;23:144-50.
69. Richmond H, Zwerner J, Kim Y et al. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007;143:1025-30. (Pubitemid 47296079)
70. Kafi R, Fisher GJ, Quan T et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140:1322-4. (Pubitemid 39473630)
71. Tran KT, Prather HB, Cockerell CJ et al. UV-A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol 2009;145:1170-4.
72. Kreuter A, Gambichler T, Weiner SM et al. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol 2008;144:1527-9.
73. Duffy KL, Green L, Harris R et al. Treatment of nephrogenic systemic fibrosis with Re-PUVA. J Am Acad Dermatol 2008;59(2 Suppl. 1):S39-40. (Pubitemid 351952421)
74. Swaminathan S, Arbiser JL, Hiatt KM et al. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J Am Acad Dermatol 2010;62:343-5.
75. Yerram P, Saab G, Karuparthi PR et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007;2:258-63.
76. Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009;53:133-7.
77. Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant 2008;23:3280-2.
78. Jan F, Segal JM, Dyer J et al. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003;143:678-81. (Pubitemid 37452802)
79. Cuffy MC, Singh M, Formica R et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011;26:1099-101.
80. Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 2008;22:803-8.
81. Leung N, Shaikh A, Cosio FG et al. The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant 2010;10:558-62.
82. Chandran S, Petersen J, Jacobs C et al. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009;53:129-32.
83. Elmholdt TR, Pedersen M, Jørgensen B et al. Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol 2011;91:478-9.
84. Kay J, Sullivan ME, Patel TV. Efficacy and safety of oral imatinib mesylate in patients with nephrogenic systemic fibrosis. Arthritis Rheum 2009;60(Suppl. 10):458 (abstract).
85. Wang Y, Alkasab TK, Narin O et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based bontrast agent guidelines. Radiology 2011;260:105-11.
86. Altun E, Martin DR, Wertman R et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Radiology 2009;253:689-96.
87. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med 2008;75:112, 114, 117.
88. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am 2009;47:833-40, vi.
89. Martinez-Tello FJ, Navas-Palacios JJ, Ricoy JR et al. Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain. Virchows Arch A Pathol Anat Histol 1982;397:261-85. (Pubitemid 13236318)
90. Mayeno AN, Gleich GJ. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale. Trends Biotechnol 1994;12:346-52. (Pubitemid 24270825)
91. Idée JM, Port M, Medina C et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88.
92. Kay J. What causes nephrogenic systemic fibrosis? The Rheumatologist 2007;3(9):1.